Estrace vs. Climara
See how Estrace and Climara compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Estrace and Climara both deliver the hormone estradiol for menopausal hot flashes, vaginal atrophy, and bone loss, but Estrace is a daily pill while Climara is a once-weekly skin patch.
Estrace is also FDA-approved for palliative treatment of certain breast and prostate cancers, a use Climara does not have.
Because Climara bypasses the liver on its way into the bloodstream, it may carry a lower clot risk than oral Estrace, though both carry boxed warnings for cardiovascular disease, dementia, and cancer risk.
Estrace vs. Climara Drug Summary
Estrace
Estrace is an oral estradiol tablet, a type of estrogen hormone therapy, used to treat menopausal hot flashes, vaginal atrophy, and hormone deficiency, and to help prevent osteoporosis. It is also FDA-approved for palliative treatment of certain breast and prostate cancers. Estrace is taken as a daily tablet in strengths from 0.5 mg to 2 mg.
Climara
Climara is a transdermal estradiol patch, the same hormone used in Estrace, applied to treat menopausal hot flashes, vaginal atrophy, and hormone deficiency, and to help prevent osteoporosis. It comes in six patch strengths and is changed just once a week. Climara is not approved for cancer treatment but is sometimes used off-label for feminizing hormone therapy.
Estrace vs. Climara Side Effects
Estrace
Climara
Estrace vs. Climara Dosage
Estrace
Climara
| STAGE | DOSE | WHEN |
| Starting dose | 0.5 mg daily | At the start |
| Maximum dose | 10 mg three times daily | If needed |
| Dose changes | 4 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 0.025 mg/day patch | At the start |
| Maximum dose | 0.1 mg/day patch | If needed |
| Dose changes | 5 increases | As tolerated |
Estrace
| STAGE | DOSE | WHEN |
| Starting dose | 0.5 mg daily | At the start |
| Maximum dose | 10 mg three times daily | If needed |
| Dose changes | 4 increases | As tolerated |
Climara
| STAGE | DOSE | WHEN |
| Starting dose | 0.025 mg/day patch | At the start |
| Maximum dose | 0.1 mg/day patch | If needed |
| Dose changes | 5 increases | As tolerated |
Estrace vs. Climara Indications
Estrace
Estrace treats moderate to severe hot flashes and vaginal atrophy caused by menopause, as well as hormone deficiency from ovarian failure, hypogonadism, or surgery. It is also FDA-approved to help prevent postmenopausal osteoporosis and, at higher doses, to palliate certain hormone-sensitive breast and prostate cancers.
Moderate to severe hot flashes of menopause
Vulvar and vaginal atrophy
Hypoestrogenism from hypogonadism or ovarian failure
Prevention of postmenopausal osteoporosis
Palliative treatment of breast or prostate cancer
Climara
Climara treats the same core menopausal symptoms as Estrace, hot flashes and vaginal atrophy, along with hormone deficiency from hypogonadism or ovarian failure. It is also FDA-approved to help prevent postmenopausal osteoporosis and is sometimes used off-label as part of feminizing hormone therapy for transgender women.
Moderate to severe hot flashes of menopause
Vulvar and vaginal atrophy
Hypoestrogenism from hypogonadism or ovarian failure
Prevention of postmenopausal osteoporosis
Off-label: feminizing hormone therapy (transgender women)
Estrace vs. Climara Pros and Cons
Estrace
Estrace is an oral estradiol tablet with one of the longest track records of any estrogen product, available in several strengths for both menopausal symptoms and hormone-sensitive cancer palliation. Because it is swallowed, it passes through the liver first, which carries a higher relative clot risk than transdermal estrogen.
Pros
FDA-approved for palliative treatment of breast and prostate cancer
Multiple oral strengths allow dosing for severe symptoms
Long-established generic tablet with decades of clinical use
Cons
Oral route means first-pass liver metabolism and higher clot risk
Requires taking a pill every day rather than weekly
2 mg tablet contains tartrazine dye, a risk for allergic patients
Climara
Climara delivers estradiol through a once-weekly patch, which may lower blood clot risk compared with oral estrogen by avoiding first-pass liver metabolism. It offers six dose strengths for fine-tuned titration but has no approved use for cancer treatment and can irritate the skin.
Pros
Once-weekly patch means far fewer doses than a daily pill
Skips first-pass liver metabolism, may lower clot risk
Six patch strengths allow precise, gradual dose adjustments
Cons
Not approved for palliative treatment of any cancer
Patch adhesive can cause skin redness or irritation
Patch is visible on the skin, which some patients dislike
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.